Abstract:Background and objective: Ginseng has been regarded as a precious medicinal herb with miraculous effects in Eastern culture. The primary chemical constituents of ginseng are saponins, and the physiological activities of ginsenosides determine their edible and medicinal value. The aim of this study is to comprehensively and systematically investigate the kinetic processes of 20(S)-protopanaxadiol (PPD) in rats and dogs, in order to promote the rational combination of ginseng as a drug and dietary ingredient. Methods: PPD was administered, and drug concentration in different biological samples were detected by liquid chromatography tandem mass spectrometry (LC/MS/MS) and radioactive tracer methods. Pharmacokinetic parameters such as absorption, bioavailability, tissue distribution, plasma protein binding rate, excretion rate, and cumulative excretion were calculated, along with inference of major metabolites. Results: This study systematically investigated the absorption, distribution, metabolism, excretion (ADME) of PPD in rats and dogs for the first time. The bioavailabilities of PPD were relatively low, with oral absorption nearly complete, and the majority underwent first-pass metabolism. PPD had a high plasma protein binding rate and was relatively evenly distributed in the body. Following oral administration, PPD underwent extensive metabolism, potentially involving one structural transformation and three hydroxylation reactions. The metabolites were primarily excreted through feces and urine, indicating the presence of enterohepatic circulation. The pharmacokinetic processes of PPD following intravenous administration aligned well with a three-compartment model. In contrast, after gastric administration, it fitted better with a two-compartment model, conforming to linear pharmacokinetics and proportional elimination. There were evident interspecies differences between rats and dogs regarding PPD, but individual variations of this drug were minimal within the same species. Conclusion: This study systematically studied the kinetic process of PPD in rats and also investigated the kinetic characteristics of PPD in dogs for the first time. These findings lay the foundation for further research on the dietary nutrition and pharmacological effects of PPD.

Pharmacokinetics of pidotimod in rats and dogs

Development and Validation of an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Quantitative Determination of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide in Dog Plasma

Pharmacokinetics and bioavailability of pidotimod in Beagle dog after oral solution and different solid preparations

A Robust LC–MS/MS Method for the Determination of Pidotimod in Different Biological Matrixes and Its Application to in Vivo and in Vitro Pharmacokinetic Studies

Propacetamol in dogs: First description of its pharmacokinetics after intravenous and oral administration

Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human

Metabolism Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic Acid Hydroxyamide (CP-544439), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans

Pharmacokinetic characteristics of single-dose pidotimod injection in Chinese healthy volunteers

A Comparison Study of Main Pharmacokinetic Parameters on Pridinol Mesylate Orally Disintegrating Tablets and Conventional Tablets in Beagle Dogs

Pharmacokinetics of Tildipirosin in Beagle Dogs

Reappraisal of Pidotimod: an immunomodulatory agent with 30-year evidence

Systematic studies on the kinetic process of 20(S)-protopanaxadiol in rats and dogs: absorption, distribution, metabolism and excretion

[Pharmacokinetics of Triptolide in Beagle Dogs].

In Vitro and in Vivo Profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a Potent, Selective, and Orally Active Canine COX-2 Inhibitor.

Detection and stability of Pidotimod by high performance liquid chromatography

Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans.

Pharmacokinetics of the novel 5-HT4 receptor agonist, DA-6886, in dogs

Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration

Exploring montelukast in dogs: A preliminary pharmacokinetic study following oral administration under fasted and fed conditions

Absorption, Metabolism, and Excretion of Taselisib (GDC-0032) , a Potent fl-Sparing PI3K Inhibitor in Rats, Dogs, and Humans

Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation